Biotechnology and Artificial Intelligence are rapidly transforming the healthcare industry. Taking a significant step in this direction, Nexentis Technologies Inc. has announced the launch of its new AI-driven biotech platform and corporate website. This platform is designed to use advanced AI algorithms to accelerate the process of discovering new medicines.
According to the company, this technology could help in developing new treatments in the future for serious diseases such as cancer and metabolic disorders.
Latest Announcement
On March 13, 2026, the company officially launched its new corporate website along with its AI-based biotechnology platform.
The platform prominently features the company’s proprietary MITOLINE AI Discovery Engine, an AI-powered system that uses advanced computational models and molecular screening technologies to identify potential drug candidates.
According to the company, the new digital platform will provide investors, researchers, and potential partners with detailed information about its research pipeline, technology, and business strategy.
Company Background
Nexentis Technologies Inc. is a biotechnology and computational drug discovery company focused on developing new medicines using AI-based technologies.
The company was previously known as N2OFF Inc. before it was rebranded as Nexentis Technologies.
The company mainly operates in the following areas:
- AI-driven drug discovery
- Precision oncology research
- Metabolic disease treatment
Its goal is to make the drug discovery process faster and more efficient through advanced technologies.
How the AI Biotech Platform Works
The company’s AI platform focuses particularly on targets related to mitochondrial biology.
Mitochondria are often referred to as the “energy factories” of cells and play an important role in many serious diseases.
The AI platform mainly works by:
- Creating digital models of complex biological targets
- Conducting virtual screening of millions of chemical molecules
- Identifying the most promising drug candidates
Through this technology, the research process can become much faster compared with traditional drug discovery methods.
Role of MitoCareX Bio
To strengthen its research capabilities, Nexentis previously acquired MitoCareX Bio Ltd..
This subsidiary focuses on research related to mitochondrial carrier proteins.
By targeting these proteins, the company aims to develop new therapies that could help treat diseases such as:
- Cancer
- Metabolic diseases
- Inflammatory disorders
Business Strategy
The company’s business model is based on biotechnology research along with some strategic investments in other sectors.
In addition to AI-driven drug discovery, the company is also involved in renewable energy projects, particularly solar energy investments.
This diversification is considered part of the company’s strategy to strengthen its long-term financial stability.
Market Opportunity
The AI-based drug discovery industry is growing rapidly.
Pharmaceutical companies are increasingly adopting AI technologies to discover new medicines because they can reduce both research costs and development time.
Experts believe that the AI-driven drug discovery market could expand significantly in the coming years, creating major opportunities for companies operating in this sector.
Challenges and Risks
Although AI-based biotechnology is considered a promising field, there are still several risks involved.
In the biotech industry, the success rate of clinical trials is often low, and it can take many years for a new drug to reach the market.
In addition, smaller biotech companies may face challenges related to funding and high research costs.
Outcome
The combination of artificial intelligence and biotechnology is creating new possibilities in the healthcare sector.
The launch of the new AI-driven biotech platform by Nexentis Technologies Inc. is considered an important step in this direction.
If the company’s AI technology proves successful, it could play a significant role in accelerating drug discovery and developing new medical treatments in the future.
Source: globenewswire
